

Supplemental digital content. eTable 2. Numbers (incidence rates) of acquired infections involving antimicrobial resistant aerobic Gram-negative bacilli and episodes of rectal colonization with extended spectrum betalactamase-producing aerobic Gram-negative bacilli.

	Pre-intervention period	Study period										Total
		1st semester	2 nd semester	3 rd semester	4 th semester	5 th semester	6 th semester	7 th semester	8 th semester	9 th semester	10 th semester	
	7,723*	3,961*	3,961*	4,113*	3,873*	3,977*	4,015*	4,062*	3,758*	4,011*	4,014*	39,745*
Microorganisms causing infection, n (%)**												
Multidrug-resistant AGNB	42 (5.43)	9 (2.27)	7 (1.77)	11 (2.67)	9 (2.26)	7 (1.76)	10 (2.49)	3 (0.74)	3 (0.80)	3 (0.75)	1 (0.25)	63 (1.59) [§]
Enterobacteriaceae												
Resistant to ceftazidime	28 (3.63)	5 (1.26)	5 (1.26)	9 (2.19)	9 (2.26)	5 (1.26)	2 (0.50)	3 (0.74)	2 (0.53)	2 (0.50)	1 (0.25)	43 (1.08) [§]
Resistant to imipenem	0	1 (0.25)	0	2 (0.49)	1 (0.26)	0	0	0	0	0	0	4 (0.10)
Resistant to ciprofloxacin	19 (2.46)	3 (0.76)	8 (2.02)	14 (3.40)	7 (1.76)	5 (1.26)	3 (0.75)	4 (0.98)	1 (0.27)	1 (0.25)	0	46 (1.16) ^{§§}
Resistant to gentamicin	10 (1.29)	6 (1.51)	6 (1.51)	4 (0.97)	8 (2.01)	8 (2.01)	3 (0.75)	3 (0.74)	2 (0.53)	2 (0.50)	1 (0.25)	43 (1.08)
Resistant to tobramycin	17 (2.20)	7 (1.77)	8 (2.02)	9 (2.19)	9 (2.26)	10 (2.51)	4 (1.00)	3 (0.74)	3 (0.80)	2 (0.50)	1 (0.25)	56 (1.41)
Resistant to amikacin resistant	6 (0.78)	1 (0.25)	2 (0.50)	7 (1.70)	2 (0.50)	5 (1.26)	3 (0.75)	0	1 (0.27)	1 (0.25)	0	22 (0.55)
Resistant to colistin	14 (1.81)	3 (0.76)	4 (1.01)	10 (2.43)	6 (1.51)	10 (2.51)	3 (0.75)	2 (0.49)	2 (0.53)	2 (0.50)	1 (0.25)	43 (1.08)
ESBL-producing	0	1 (0.3)	3 (0.8)	1 (0.2)	3 (0.8)	1 (0.3)	1 (0.25)	1 (0.24)	1 (0.3)	0	0	12 (0.3)
<i>Pseudomonas aeruginosa</i>												
Resistant to ceftazidime	6 (0.78)	1(0.25)	0	4 (0.97)	0	0	1 (0.25)	0	0	1 (0.25)	1 (0.25)	8 (0.20) ^{§§}
Resistant to imipenem	7 (0.91)	4 (1.01)	4 (1.01)	7 (1.70)	7 (1.76)	3 (0.75)	6 (1.49)	2 (0.49)	1 (0.27)	1 (0.25)	0	35 (0.88)
Resistant to ciprofloxacin	12 (1.55)	4 (1.01)	2 (0.50)	3 (0.73)	2 (0.50)	5 (1.26)	7 (1.74)	4 (0.98)	1 (0.27)	0	0	24 (0.60) ^{§§}
Resistant to gentamicin	10 (1.29)	5 (1.26)	2 (0.50)	4 (0.97)	5 (1.26)	4 (1.01)	5 (1.25)	4 (0.98)	1 (0.27)	1 (0.25)	1 (0.25)	32 (0.81)
Resistant to tobramycin	10 (1.29)	4 (1.01)	2 (0.50)	3 (0.73)	4 (1.01)	4 (1.01)	2 (0.50)	4 (0.98)	1 (0.27)	0	0	24 (0.60) ^{§§}
Resistant to amikacin	7 (0.91)	1(0.25)	0	0	1(0.26)	0	1 (0.25)	0	0	0	1 (0.25)	4 (0.10) ^{§§}
Resistant to colistin	0	0	0	0	1 (0.26)	0	0	0	0	0	0	1 (0.03)
Irrespective of antimicrobial resistance	27 (3.50)	7 (1.77)	8 (2.02)	16 (3.89)	11 (2.77)	8 (2.01)	11 (2.74)	10 (2.46)	2 (0.53)	4 (1.00)	4 (1.00)	81 (2.04)
Other glucose-nonfermenting AGNB												
Resistant to ceftazidime	13 (1.68)	0	2 (0.50)	2 (0.49)	3 (0.75)	0	1 (0.25)	0	1 (0.27)	2 (0.50)	2 (0.50)	13 (0.33) [§]
Resistant to imipenem	3	1 (0.25)	2 (0.50)	2 (0.49)	3 (0.75)	0	3 (0.75)	0	2 (0.53)	2 (0.50)	1 (0.25)	16 (0.40)
Resistant to ciprofloxacin	6 (0.78)	1(0.25)	2 (0.50)	2(0.49)	1(0.26)	0	2 (0.50)	0	1 (0.27)	0	0	9 (0.23) ^{§§}
Resistant to gentamicin	5 (0.65)	1 (0.25)	2 (0.50)	2 (0.49)	3 (0.75)	0	3 (0.75)	0	1 (0.27)	1 (0.25)	1 (0.25)	14 (0.35)
Resistant to tobramycin	10 (1.29)	1 (0.25)	2 (0.50)	1 (0.24)	3 (0.75)	0	3 (0.75)	0	2 (0.53)	1 (0.25)	1 (0.25)	14 (0.35) ^{§§}
Resistant to amikacin	8 (1.04)	1 (0.25)	2 (0.50)	1 (0.24)	3 (0.75)	0	3 (0.75)	0	1 (0.27)	1 (0.25)	1 (0.25)	13 (0.33) ^{§§}
Resistant to colistin	-	1(0.25)	0	0	0	0	1 (0.25)	0	1 (0.27)	0	0	3 (0.08)
AGNB resistant to both colistin and tobramycin	7 (0.91)	4 (1.01)	5 (1.26)	6 (1.46)	3 (0.75)	6 (1.51)	3 (0.75)	1 (0.25)	3 (0.80)	1 (0.25)	0	32 (0.81)
Gram positive cocci												
Methicillin resistant <i>Staphylococcus aureus</i>	7 (0.91)	2 (0.50)	2 (0.50)	2 (0.49)	2 (0.50)	0	1 (0.25)	0	3 (0.80)	4 (1.00)	0	16 (0.40)
Coagulase negative staphylococcus	10 (1.29)	1 (0.25)	3 (0.76)	4 (0.97)	4 (1.01)	2 (0.50)	1 (0.25)	3 (0.74)	1 (0.27)	5 (1.25)	1 (0.25)	25 (0.63)
Methicillin susceptible <i>Staphylococcus aureus</i>	15 (1.94)	0	0	0	1(0.26)	1 (0.25)	1 (0.25)	2 (0.49)	2 (0.53)	0	1 (0.25)	8 (0.20)
Enterococcus	12 (1.55)	4 (1.01)	1 (0.25)	7 (1.70)	7 (1.76)	8 (2.01)	3 (0.75)	3 (0.74)	4 (1.06)	4 (1.0)	1 (0.25)	42 (1.06)
Gram positive cocci (any type)	60 (7.77)	9 (2.27)	7 (1.77)	17 (4.13)	16 (4.02)	11 (2.77)	5 (1.25)	8 (1.97)	9 (2.39)	14 (3.49)	3 (0.75)	99 (2.49) [§]
Fungi: <i>Aspergillus</i> or <i>Candida</i>	11 (1.42)	2 (0.50)	1 (0.25)	3 (0.73)	3 (0.75)	4 (1.01)	2 (0.50)	2 (0.49)	4 (1.06)	1 (0.25)	3 (0.75)	23 (0.58) ^{§§}
Any microorganism (bacterial or fungal, irrespective of antimicrobial resistance)	172 (22.27)	28 (7.07)	30 (7.57)	64 (15.56)	56 (14.08)	43 (10.81)	31 (7.72)	33 (8.12)	20 (5.32)	26 (6.48)	23 (5.73)	345 (8.68) [§]
Any AGNB, irrespective of antimicrobial resistance	108 (13.98)	19 (4.80)	19 (4.80)	39 (9.48)	32 (8.05)	21 (5.28)	23 (5.73)	19 (4.68)	10 (2.66)	10 (2.49)	14 (3.49)	206 (5.18) [§]
Acquired colonization with ESBL-producing AGNB, n (%)**	-	9 (2.27)	21 (5.30)	10 (2.43)	18 (4.6)	13 (3.3)	8 (2.0)	11 (2.7)	12 (3.2)	10 (2.5)	5 (1.2)	117 (2.9)

* Number of patients-days. ** n denotes the numbers of episodes and the incidence rate (‰) is expressed per 1,000 patients-days. AGNB: aerobic Gram negative bacilli. ESBL: extended spectrum β -lactamase. [§] Versus pre-intervention period, P<0.001. ^{§§} Versus pre-intervention period, P<0.05.